{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:34:15Z","timestamp":1792823655735,"version":"4.5.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2019CDF-2662-Pfkelch13"],"award-info":[{"award-number":["TMA2019CDF-2662-Pfkelch13"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1R25TW011213"],"award-info":[{"award-number":["1R25TW011213"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Artemisinin resistance threatens malaria control and elimination efforts globally. Recent studies have reported the emergence of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    parasites tolerant to artemisinin agents in sub-Saharan Africa, including Uganda. The current study assessed the day 3 parasite clearance and its correlation with\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum K13<\/jats:italic>\n                    propeller gene (\n                    <jats:italic>pfkelch13<\/jats:italic>\n                    ) mutations in\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum<\/jats:italic>\n                    parasites isolated from patients with uncomplicated malaria under artemether-lumefantrine (AL) treatment. This study enrolled 100\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum-<\/jats:italic>\n                    positive patients to whom AL was prescribed between 09\/September\/2022 and 06\/November\/2022. Blood samples were collected in EDTA tubes before treatment initiation (day 0) and on day 3. Parasitemia was assessed by microscopy from blood smears and quantitative polymerase chain reaction (qPCR) from the DNA extracted. The day 0 parasite\n                    <jats:italic>K13<\/jats:italic>\n                    gene was sequenced using Sanger sequencing. Sequence data were analysed using MEGA\n                    <jats:italic>version<\/jats:italic>\n                    11 software. The data were analysed using STATA\n                    <jats:italic>version<\/jats:italic>\n                    15, and the Mann\u2012Whitney U test was used to compare PCR parasite clearance on day 3 using the comparative CT value method and\n                    <jats:italic>pfkelch13<\/jats:italic>\n                    mutations. The prevalence of day 3 parasitaemia was 24% (24\/100) by microscopy and 63% (63\/100) by qPCR from the AL-treated patients.\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum K13<\/jats:italic>\n                    -propeller gene polymorphism was detected in 18.8% (15\/80) of the day 0 DNA samples. The\n                    <jats:italic>K13<\/jats:italic>\n                    mutations found were C469Y, 12.5% (10\/80); A675V, 2.5% (2\/80); A569S, 1.25%, (1\/80), A578S, 1.25%, (1\/80) and; F491S, 1.25%, (1\/80) a new allele not reported anywhere. The C469Y mutation, compared to the wild-type, was associated with delayed parasite clearance\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0278, Hodges-Lehmann estimation 3.2108 on the log scale, (95%CI 1.7076, 4.4730). There was a high prevalence of day 3\n                    <jats:italic>P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum<\/jats:italic>\n                    among malaria patients treated using artemether-lumefantrine. We conclude the presence of the\n                    <jats:italic>K13<\/jats:italic>\n                    mutation associated with artemisinin resistance\n                    <jats:italic>by P<\/jats:italic>\n                    .\n                    <jats:italic>falciparum<\/jats:italic>\n                    in Adjumani district, Uganda, necessitates regular surveillance of the effectiveness and efficacy of artemether-lumefantrine in the country.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0305064","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:32:04Z","timestamp":1717594324000},"page":"e0305064","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-7762","authenticated-orcid":true,"given":"Martin Kamilo","family":"Angwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Mwebaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam Lubwama","family":"Nsobya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vudriko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saviour","family":"Dralabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Omali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Agnes","family":"Tumwebaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Ocan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"pone.0305064.ref001","unstructured":"World Health Organization. World malaria report 2022 [Internet]. 2022 [cited 2023 Dec 2]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022"},{"key":"pone.0305064.ref002","unstructured":"World Health Organization. World malaria report 2023 [Internet]. 2023. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023"},{"key":"pone.0305064.ref003","article-title":"Uganda Malaria Indicator Survey 2018\u20132019.","year":"2020","journal-title":"The Republic of Uganda Ministry of Health"},{"key":"pone.0305064.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010007","article-title":"Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda.","author":"H Bukirwa","year":"2006"},{"key":"pone.0305064.ref005","article-title":"Moses R Kamya, Bridget K Nzarubara, Grant Dorsey, Philip J. Rosenthal. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial","author":"Arthur Mpimbaza Sarah G Staedke","journal-title":"Internet]. Available from: www.thelancet.com"},{"key":"pone.0305064.ref006","volume-title":"Guidelines for the treatment of malaria","author":"Organization WH","year":"2015"},{"issue":"4","key":"pone.0305064.ref007","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4269\/ajtmh.20-0250","article-title":"Malaria transmission, infection, and disease following sustained indoor residual spraying of insecticide in Tororo, Uganda","volume":"103","author":"JI Nankabirwa","year":"2020","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"1","key":"pone.0305064.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-017-1871-3","article-title":"Rapid reduction of malaria following introduction of vector control interventions in Tororo District, Uganda: a descriptive study.","volume":"16","author":"DW Oguttu","year":"2017","journal-title":"Malar J."},{"issue":"11","key":"pone.0305064.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002167","article-title":"Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study.","volume":"13","author":"A Katureebe","year":"2016","journal-title":"PLoS Med"},{"issue":"23","key":"pone.0305064.ref010","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMoa2002820","article-title":"Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.","volume":"383","author":"TK Kwambai","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"pone.0305064.ref011","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.05141-14","article-title":"Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from Ugandan children","volume":"59","author":"P Tumwebaze","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0305064.ref012","article-title":"Malaria chemoprevention and drug resistance: a review of the literature and policy implications.","volume":"21","author":"V. Plowe C","year":"2022","journal-title":"Malaria Journal. BioMed Central Ltd"},{"issue":"4","key":"pone.0305064.ref013","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.inhe.2010.07.002","article-title":"Challenges to implementation of artemisinin combination therapy policy in Uganda.","volume":"2","author":"V Batwala","year":"2010","journal-title":"Int Health.Dec"},{"issue":"1","key":"pone.0305064.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-023-04600-8","article-title":"Pharmacopeial quality of artemether\u2013lumefantrine anti-malarial agents in Uganda.","volume":"22","author":"M Ocan","year":"2023","journal-title":"Malar J"},{"key":"pone.0305064.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-2109-3","article-title":"Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries.","volume":"15","author":"M Ocan","year":"2015","journal-title":"BMC Public Health"},{"issue":"7481","key":"pone.0305064.ref016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"F Ariey","year":"2014","journal-title":"Nature"},{"issue":"10","key":"pone.0305064.ref017","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"A Uwimana","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"pone.0305064.ref018","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"A Uwimana","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"pone.0305064.ref019","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria","volume":"385","author":"B Balikagala","year":"2021","journal-title":"Africa. New England Journal of Medicine"},{"issue":"6","key":"pone.0305064.ref020","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","article-title":"Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda","volume":"223","author":"V Asua","year":"2021","journal-title":"J Infect Dis"},{"key":"pone.0305064.ref021","first-page":"13","author":"PK Tumwebaze","year":"2022","journal-title":"Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda"},{"key":"pone.0305064.ref022","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-3156.2002.00974.x","article-title":"Increasing antimalarial drug resistance in Uganda and revision of the national drug policy.","volume":"7","author":"MR Kamya","year":"2002","journal-title":"Tropical Medicine and International Health"},{"issue":"3","key":"pone.0305064.ref023","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.actatropica.2005.06.003","article-title":"Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative","volume":"95","author":"H Sendagire","year":"2005","journal-title":"Acta Trop"},{"issue":"1","key":"pone.0305064.ref024","doi-asserted-by":"crossref","DOI":"10.1186\/s12939-020-01371-5","article-title":"Exploring country-wide equitable government health care facility access in Uganda.","volume":"20","author":"N. Dowhaniuk","year":"2021","journal-title":"Int J Equity Health."},{"issue":"4","key":"pone.0305064.ref025","doi-asserted-by":"crossref","DOI":"10.18549\/PharmPract.2019.4.1622","article-title":"Challenges with accessing health care for young children presumed to have malaria in the rural district of Butaleja, Uganda: A qualitative study.","volume":"17","author":"A Rahimi","year":"2019","journal-title":"Pharm Pract (Granada)."},{"key":"pone.0305064.ref026","article-title":"2018\u201319 Uganda Malaria Indicator Survey (UMIS) Atlas of Key Indicators.","author":"National Malaria Control Division (NMCD) & Uganda Bureau of Statistics (UBOS)","year":"2018"},{"issue":"8","key":"pone.0305064.ref027","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/JCM.00276-11","article-title":"Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of plasmodium by amplifying RNA and DNA of the 18S rRNA genes","volume":"49","author":"E Kamau","year":"2011","journal-title":"J Clin Microbiol"},{"key":"pone.0305064.ref028","article-title":"Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia","author":"G Tadele","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0305064.ref029","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method.","volume":"3","author":"TD Schmittgen","year":"2008","journal-title":"Nat Protoc."},{"issue":"14","key":"pone.0305064.ref030","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1017\/S003118201400033X","article-title":"Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment","volume":"141","author":"M Betson","year":"2014","journal-title":"Parasitology"},{"issue":"1","key":"pone.0305064.ref031","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-020-03287-5","article-title":"Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: A randomized controlled trial.","volume":"19","author":"LE Mhamilawa","year":"2020","journal-title":"Malar J."},{"issue":"5","key":"pone.0305064.ref032","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.18-0729","article-title":"Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether\u2013Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania","volume":"100","author":"R Mwaiswelo","year":"2019","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"8","key":"pone.0305064.ref033","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1590\/0074-0276130167","article-title":"Evidence of an increased incidence of day 3 parasitaemia in Suriname: An indicator of the emerging resistance of Plasmodium falciparum to artemether","volume":"108","author":"SGS Vreden","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pone.0305064.ref034","article-title":"Artemisinin resistance and artemisinin-based combination therapy efficacy (Status report\u2014August 2018) [Internet].","author":"Health Organization W.","year":"2018"},{"key":"pone.0305064.ref035","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.2147\/IDR.S341357","article-title":"Limited polymorphism in plasmodium falciparum artemisinin resistance kelch13-propeller gene among clinical isolates from bushenyi district, uganda.","volume":"14","author":"JN Maniga","year":"2021","journal-title":"Infect Drug Resist."},{"issue":"7","key":"pone.0305064.ref036","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/infdis\/jiy637","article-title":"Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children","volume":"219","author":"A Yeka","year":"2019","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"pone.0305064.ref037","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-021-04021-5","article-title":"Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.","volume":"20","author":"C Ebong","year":"2021","journal-title":"Malar J."},{"issue":"9469","key":"pone.0305064.ref038","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(05)66416-1","article-title":"Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial","volume":"365","author":"P Piola","year":"2005","journal-title":"The Lancet"},{"issue":"12","key":"pone.0305064.ref039","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/infdis\/jit431","article-title":"Residual Plasmodium falciparum parasitemia in kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence","volume":"208","author":"KB Beshir","year":"2013","journal-title":"Journal of Infectious Diseases"},{"issue":"3","key":"pone.0305064.ref040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01818-18","article-title":"Changing molecular markers of antimalarial drug sensitivity across Uganda","volume":"63","author":"V Asua","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0305064.ref041","first-page":"631","article-title":"Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda","volume":"215","author":"P Tumwebaze","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"pone.0305064.ref042","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa2211803","article-title":"Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda.","volume":"389","author":"MD Conrad","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"pone.0305064.ref043","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMc2117480","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"386","author":"BH Stokes","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0305064.ref044","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-021-03715-0","article-title":"Molecular surveillance of drug resistance: Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in Kelch protein propeller (K13) domain from Southern Pakistan.","volume":"20","author":"NK Ghanchi","year":"2021","journal-title":"Malar J."},{"key":"pone.0305064.ref045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/infdis\/jiv414","article-title":"Is the A578S single-nucleotide polymorphism in K13-propeller a marker of emerging resistance to artemisinin among plasmodium falciparum in Africa?","volume":"213","author":"O Ma\u00efga-Ascofar\u00e9","year":"2016","journal-title":"Journal of Infectious Diseases. Oxford University Press"},{"key":"pone.0305064.ref046","article-title":"A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa.","volume":"16","author":"L Ndwiga","year":"2021","journal-title":"International Journal for Parasitology: Drugs and Drug Resistance"},{"key":"pone.0305064.ref047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268095","article-title":"Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda","volume":"17","author":"M Ocan","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"pone.0305064.ref048","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3201\/eid2107.150213","article-title":"Slow clearance of Plasmodium falciparum in severe pediatric malaria, Uganda, 2011\u20132013","volume":"21","author":"M Hawkes","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"25","key":"pone.0305064.ref049","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","article-title":"A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.","volume":"374","author":"D M\u00e9nard","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0305064.ref050","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-016-1095-y","article-title":"Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children.","volume":"15","author":"J Muwanguzi","year":"2016","journal-title":"Malar J."},{"issue":"1","key":"pone.0305064.ref051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1777-7","article-title":"Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda","volume":"16","author":"M Ocan","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"8","key":"pone.0305064.ref052","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","article-title":"High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine","volume":"225","author":"J Straimer","year":"2022","journal-title":"Journal of Infectious Diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:32:51Z","timestamp":1717594371000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305064"}},"subtitle":[],"editor":[{"given":"Myat Htut","family":"Nyunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305064","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]}}}